NNZ-2591
Experimental drug for neurodevelopmental disorders
| NNZ-2591 | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
NNZ-2591 is an experimental drug being investigated for the treatment of various neurodevelopmental disorders. It is a synthetic analog of the naturally occurring neuropeptide cyclo-glycyl-proline (cGP), which is known to have neuroprotective and cognitive-enhancing properties.
Mechanism of Action[edit | edit source]
NNZ-2591 is believed to exert its effects by modulating the activity of insulin-like growth factor 1 (IGF-1) and its receptor. IGF-1 is a hormone similar in molecular structure to insulin and plays an important role in childhood growth and continues to have anabolic effects in adults. By influencing IGF-1 signaling pathways, NNZ-2591 may help to restore normal function in neural circuits that are disrupted in neurodevelopmental disorders.
Potential Therapeutic Uses[edit | edit source]
NNZ-2591 is being studied for its potential to treat several neurodevelopmental disorders, including:
These conditions are characterized by intellectual disability, developmental delay, and other neurological symptoms. NNZ-2591 aims to improve cognitive function and reduce the severity of these symptoms.
Clinical Trials[edit | edit source]
As of the latest updates, NNZ-2591 is undergoing various stages of clinical trials to evaluate its safety and efficacy. Early-phase trials have shown promising results in terms of tolerability and potential therapeutic benefits. Further studies are needed to confirm these findings and to determine the optimal dosing regimen.
Research and Development[edit | edit source]
The development of NNZ-2591 is spearheaded by Neuren Pharmaceuticals, a company focused on developing therapies for neurological disorders. The research involves collaboration with academic institutions and clinical research organizations to advance the understanding of NNZ-2591's effects and its potential as a treatment option.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
